Search research articles
Contact Us
Filters
Showing results (121-130 of 140) with videos related to
Page
of 14
Sort By:
The Oncologist
|
May 30, 2024
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
Julia L Glade Bender, Kerice Pinkney, Paul M Williams, et al.
Journal of the National Cancer Institute
|
May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Susan N Chi, Joanna S Yi, P Mickey Williams, et al.
Oncotarget
|
November 20, 2020
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas
Geraldine O'Sullivan Coyne, Shivaani Kummar, Robert S Meehan, et al.
JCO Precision Oncology
|
December 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, et al.
Investigational New Drugs
|
January 25, 2024
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Oluwadunni E Emiloju, Jun Yin, Emily Koubek, et al.
JCO Precision Oncology
|
August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
Filip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
Oncotarget
|
March 4, 2021
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors
Naoko Takebe, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2025
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Eudocia Q Lee, Brian M Alexander, Carlos G Romo, et al.
The Oncologist
|
June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G
Marie V Nelson, AeRang Kim, P Mickey Williams, et al.
JCO Precision Oncology
|
October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Sarah Scollon, Sharon E Plon, Steven Joffe, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 140) with videos related to
Sort By:
Page
of 14
The Oncologist
|
May 30, 2024
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
Julia L Glade Bender, Kerice Pinkney, Paul M Williams, et al.
Journal of the National Cancer Institute
|
May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Susan N Chi, Joanna S Yi, P Mickey Williams, et al.
Oncotarget
|
November 20, 2020
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas
Geraldine O'Sullivan Coyne, Shivaani Kummar, Robert S Meehan, et al.
JCO Precision Oncology
|
December 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, et al.
Investigational New Drugs
|
January 25, 2024
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Oluwadunni E Emiloju, Jun Yin, Emily Koubek, et al.
JCO Precision Oncology
|
August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
Filip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
Oncotarget
|
March 4, 2021
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors
Naoko Takebe, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2025
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Eudocia Q Lee, Brian M Alexander, Carlos G Romo, et al.
The Oncologist
|
June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G
Marie V Nelson, AeRang Kim, P Mickey Williams, et al.
JCO Precision Oncology
|
October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Sarah Scollon, Sharon E Plon, Steven Joffe, et al.
Page
of 14